AstraZeneca has announced a surprise £300 million investment in UK drug development, reversing a previous decision to halt expansion plans. The pharmaceutical giant had paused a £200 million expansion of its Cambridge research site and scrapped a £450 million vaccine plant in Merseyside last year, citing economic viability concerns.
Investment Details
The new funding will complete the Rosalind Franklin building at AstraZeneca's Cambridge campus and develop a 'lab of the future' using digital and data tools to advance drug development. The investment also includes upgrades to the Macclesfield site.
Government Praise
Prime Minister Sir Keir Starmer hailed the commitment as 'significant,' stating it would 'futureproof thousands of jobs in Macclesfield and Cambridge.' He credited the US-UK pharmaceutical arrangement, finalised earlier in April, for enabling the investment.
AstraZeneca CEO Pascal Soriot thanked the British government 'for their efforts to improve access for patients,' noting four new drug approvals since the start of the year. He expressed hope for further enhancements to the access and reimbursement environment to build a strong life sciences sector.
Context
Last year, AstraZeneca paused a planned £200 million expansion of its Cambridge research site and scrapped proposals for a £450 million vaccine plant in Merseyside. Soriot explained at the time that the company 'couldn't make the business case work and couldn't make the investment economically viable.'
The new investment comes as AstraZeneca reported better-than-expected earnings, driven by demand for its cancer and rare disease drugs. The company has warned that Europe risks missing out on new medicines under the new most-favored-nation pricing policy environment.
